Cyclacel pulls the plug on Daiichi-partnered chemo — 8 years after a failed PhIII in AML
Hovering around penny stock territory, New Jersey-based Cyclacel Pharmaceuticals $CYCC said yesterday it’s finally going to call it quits on a Daiichi Sankyo-partnered cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.